More on XNCR
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $25.84 |
|
|||
| Open | $25.52 | ||||
| 52 Wk High | $26.50 | ||||
| 52 Wk Low | $9.89 | ||||
| Day High | $25.81 | ||||
| Day Low | $24.42 | ||||
| P/E | N/A | ||||
| EPS | $-0.51 | ||||
| Volume | 1,458,065 | ||||
- Xencor reports Phase 1 dose data for kidney cancer drug XmAb819
- Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
- Xencor to webcast Phase 1 results of XmAb819 in kidney cancer
- Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
- RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'
- Raymond James Updates Healthcare Top Picks for October
- Wells Fargo Assumes Xencor, Inc. (XNCR) at Overweight
- Xencor, Inc. (XNCR) PT Raised to $29 at Truist Securities
- Xencor, Inc. (XNCR) PT Raised to $35 at Barclays
- Xencor, Inc. (XNCR) PT Raised to $21 at JPMorgan
Entities mentioned with XNCR
- Earnings | View Related Stories »
- 13G | View Related Stories »
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Definitive Agreement | View Related Stories »
- RBC Capital | View Related Stories »
- Show More...
